Shu Deng Selected Research

bufogenin

7/2022

Resibufogenin inhibits the malignant characteristics of multiple myeloma cells by blocking the PI3K/Akt signaling pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shu Deng Research Topics

Disease

6	Neoplasms (Cancer) 12/2021 - 07/2020
4	Aplastic Anemia (Anemia, Hypoplastic) 09/2022 - 09/2018
4	Lymphoma (Lymphomas) 01/2022 - 07/2020
3	Infections 01/2022 - 02/2009
3	Inflammation (Inflammations) 01/2020 - 01/2018
2	Periodontitis 03/2018 - 01/2018
1	Multiple Myeloma 07/2022
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 03/2022
1	Thrombotic Thrombocytopenic Purpura 03/2022
1	Glioma (Gliomas) 12/2021
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 03/2021
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021
1	Diarrhea 01/2020
1	Abdominal Pain (Pain, Abdominal) 01/2020
1	Bone Resorption 01/2020
1	Peri-Implantitis 01/2020
1	Dysbiosis 01/2020
1	Back Pain (Backache) 01/2019
1	Anemia 01/2019
1	Nausea 01/2019
1	Thrombocytopenia (Thrombopenia) 01/2019
1	Vomiting 01/2019
1	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2019
1	Postoperative Nausea and Vomiting (PONV) 01/2019
1	Autoimmune Diseases (Autoimmune Disease) 11/2018
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 11/2018
1	Acquired Immunodeficiency Syndrome (AIDS) 11/2018
1	Alveolar Bone Loss 01/2018
1	Fatigue 01/2015
1	Parasitemia 05/2013

Drug/Important Bio-Agent (IBA)

3	CurcuminIBA 01/2022 - 01/2021
3	Therapeutic UsesIBA 01/2022 - 01/2019
3	HomoharringtonineIBA 01/2022 - 01/2021
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 09/2018
3	CytokinesIBA 01/2021 - 03/2018
3	Messenger RNA (mRNA)IBA 01/2020 - 02/2009
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 01/2020
1	icariinIBA 09/2022
1	bufogeninIBA 07/2022
1	Rituximab (Mabthera)FDA Link 03/2022
1	Peptide Nucleic AcidsIBA 01/2022
1	DefensinsIBA 05/2021
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 03/2021
1	Cadherins (E-Cadherin)IBA 01/2021
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2021
1	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 01/2021
1	ORALIT (ORS)IBA 12/2020
1	Interferon-gamma (Interferon, gamma)IBA 12/2020
1	MatrinesIBA 07/2020
1	AlkaloidsIBA 07/2020
1	Toll-Like Receptor 4IBA 01/2020
1	Tartrate-Resistant Acid PhosphataseIBA 01/2020
1	Etoposide (VP 16)FDA LinkGeneric 01/2019
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019
1	Prednisone (Sone)FDA LinkGeneric 01/2019
1	Vincristine (Oncovin)FDA LinkGeneric 01/2019
1	Rheumatoid FactorIBA 11/2018
1	AutoantibodiesIBA 11/2018
1	Antinuclear AntibodiesIBA 11/2018
1	MicroRNAs (MicroRNA)IBA 03/2018
1	Toll-Like Receptor 9IBA 01/2018
1	Interleukin-10 (Interleukin 10)IBA 01/2018
1	OligodeoxyribonucleotidesIBA 01/2018
1	CD40 Ligand (CD40L)IBA 01/2018
1	GuanosineIBA 01/2018
1	CytidineIBA 01/2018
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Phosphates (Orthophosphate)IBA 01/2018
1	nitinolIBA 01/2015
1	DNA VaccinesIBA 05/2013
1	Indicators and Reagents (Reagents)IBA 02/2009

Therapy/Procedure

2	Therapeutics 03/2021 - 02/2009
2	Ligation 01/2020 - 01/2018
1	Plasmapheresis 03/2022
1	Radiotherapy 12/2021
1	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 01/2021
1	Epidural Anesthesia 01/2019
1	Analgesia 01/2019
1	Nerve Block (Nerve Blocks) 01/2019
1	Orthopedic Procedures 01/2019